09:25 AM EDT, 08/21/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday the US Food and Drug Administration has granted orphan drug designation to atumelnant, its oral drug candidate for classic congenital adrenal hyperplasia.

The company said the designation follows phase 2 trial results that indicated reductions in key biomarkers and clinical symptoms in adults with the condition.

Crinetics said it plans to begin enrollment in a phase 3 study in adults and a phase 2/3 study in children in H2 2025.